Long-term Outcome of the REMAGUS 02 Trial, a Multicenter Randomised Phase II Trial in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy With or Without Celecoxib or Trastuzumab According to HER2 Status
The REMAGUS-02 multicenter randomized phase II trial showed that the addition to neoadjuvant chemotherapy of trastuzumab in patients with localized HER2-positive breast cancer increased the pathological complete response rate and that the addition of celecoxib in HER2-negative cases did not increase the pathological complete response rate. This article the long-term follow-up results for disease-free survival and overall survival, indicating that celecoxib combined with neoadjuvant chemotherapy provided neither pathological complete response rate benefit nor survival benefit in patients with HER2-negative breast cancer.
Eur J Cancer
In The News
In The Literature